Tirzepatide research and evidence overview

Tirzepatide has one of the most complete evidence bases of any peptide: two finished phase 3 programs (SURPASS in type 2 diabetes, SURMOUNT in obesity), a positive phase 3 result in obstructive sleep apnea, three FDA-approved indications across the Mounjaro and Zepbound brands, and published follow-on data on weight regain and body composition. This is approved medicine territory — the open questions are about additional uses and long-term outcomes, not whether the drug works. The trials below are the load-bearing ones, with their actual numbers.

Tirzepatide began as Eli Lilly compound LY3298176, described in 2018 as a fatty-acid-modified peptide engineered for dual GIP and GLP-1 receptor agonism and once-weekly injection. The discovery paper is worth knowing because it established the drug's central claim experimentally: in receptor-knockout mice, the glucose effects required both receptors, and in early human studies its glucose and weight effects already exceeded those of selective GLP-1 agonists (Coskun et al., Molecular Metabolism 2018). That made the dual-incretin hypothesis testable at scale — which is what the two phase 3 programs did.

The SURPASS program ran tirzepatide against placebo, insulin regimens, and an active incretin comparator across the type 2 diabetes treatment spectrum, supporting the May 2022 Mounjaro approval (Mounjaro label, DailyMed). The most-cited trial is SURPASS-2 (n=1,879), the direct comparison with semaglutide 1 mg over 40 weeks:

• HbA1c: −2.01, −2.24, and −2.30 percentage points at tirzepatide 5, 10, and 15 mg versus −1.86 for semaglutide — superior at every dose.
• Weight: 1.9, 3.6, and 5.5 kg greater reduction than semaglutide (all p<0.001).

(Frías et al., NEJM 2021.) One caveat belongs next to that result: the comparator was semaglutide's 1 mg diabetes dose, not the 2.4 mg dose later approved for obesity — a nuance unpacked on the semaglutide vs tirzepatide page.

SURMOUNT-1 (n=2,539 adults with obesity or overweight, without diabetes) is the registrational obesity trial. Over 72 weeks, mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo; 50–57% of the two higher-dose groups lost at least 20% of body weight, and adverse events were predominantly gastrointestinal and mild to moderate (Jastreboff et al., NEJM 2022).

Two companion results answer the questions SURMOUNT-1 raised:

• What happens on stopping? SURMOUNT-4 gave everyone tirzepatide for 36 weeks (mean −20.9%), then randomized 670 participants to continue or switch to placebo for 52 weeks. Continuers lost a further 5.5% (−25.3% total); those switched to placebo regained 14.0% (Aronne et al., JAMA 2024). This is the key evidence that tirzepatide manages obesity rather than curing it — see also can you regain weight after stopping peptides.

• What kind of weight is lost? In the SURMOUNT-1 DXA substudy (n=160), tirzepatide reduced fat mass by 33.9% and lean mass by 10.9%; the lost weight was roughly 75% fat and 25% lean — the same proportions as placebo-group weight loss (Look et al., Diabetes Obes Metab 2025).

The SURMOUNT-OSA program ran two parallel phase 3 trials in moderate to severe obstructive sleep apnea with obesity — one in people not using positive airway pressure (PAP) therapy, one in PAP users. Tirzepatide reduced the apnea–hypopnea index by 25.3 and 29.3 events per hour respectively, versus about 5 with placebo (both p<0.001) (Malhotra et al., NEJM 2024). The FDA approved the OSA indication for Zepbound in December 2024, calling it the first medication for obstructive sleep apnea (FDA press announcement).

Active research directions — cardiovascular outcomes, chronic kidney disease, heart failure with preserved ejection fraction, metabolic liver disease, and head-to-head work within the incretin class, including against the investigational triple agonist retatrutide — remain developing evidence, not approved uses.

Three habits keep this literature in perspective. First, match the population to the claim: SURPASS results are from people with type 2 diabetes, SURMOUNT from people with obesity — effect sizes do not transfer to other groups. Second, note the support structure: every trial delivered the drug with verified dosing, gradual titration, lifestyle counselling, and monitoring, none of which come with a gray-market vial. Third, distinguish approved indications (diabetes, weight management, OSA) from investigational directions, however promising the early data. The trials are real and unusually strong; the marketing built on top of them frequently is not.